Total Payments
$10,103
2024 Payments
$3,516
Companies
37
Transactions
126
Medicare Patients
1,758
Medicare Billing
$242,511
Payment Breakdown by Category
Consulting$6,652 (65.8%)
Other$1,777 (17.6%)
Food & Beverage$1,258 (12.5%)
Education$416.00 (4.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,652 | 21 | 65.8% |
| Food and Beverage | $1,258 | 83 | 12.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,227 | 6 | 12.1% |
| Honoraria | $550.00 | 3 | 5.4% |
| Education | $416.00 | 13 | 4.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,148 | 7 | $0 (2024) |
| VERTEX PHARMACEUTICALS INCORPORATED | $1,833 | 5 | $0 (2024) |
| GENZYME CORPORATION | $849.50 | 6 | $0 (2022) |
| AbbVie, Inc. | $615.00 | 2 | $0 (2019) |
| BeiGene, Ltd. | $600.00 | 2 | $0 (2023) |
| COMSORT, Inc | $550.00 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $419.12 | 17 | $0 (2024) |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2 | $0 (2020) |
| Alnylam Pharmaceuticals Inc. | $310.00 | 1 | $0 (2022) |
| Millennium Pharmaceuticals, Inc. | $307.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,516 | 16 | AstraZeneca Pharmaceuticals LP ($2,100) |
| 2023 | $985.34 | 19 | BeiGene, Ltd. ($600.00) |
| 2022 | $950.56 | 10 | Alnylam Pharmaceuticals Inc. ($310.00) |
| 2021 | $1,329 | 13 | GENZYME CORPORATION ($400.00) |
| 2020 | $797.88 | 6 | Athenex Pharmaceutical Division, LLC ($350.00) |
| 2019 | $833.64 | 8 | AbbVie, Inc. ($615.00) |
| 2018 | $545.17 | 7 | COMSORT, Inc ($150.00) |
| 2017 | $1,146 | 47 | Millennium Pharmaceuticals, Inc. ($307.00) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Oncology | ||||||
| 10/07/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 09/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.03 | General |
| Category: Oncology | ||||||
| 07/10/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 06/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.48 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/09/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $406.67 | General |
| 04/23/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Oncology | ||||||
| 04/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $426.27 | General |
| 03/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.53 | General |
| Category: Oncology | ||||||
| 12/20/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.31 | General |
| Category: Oncology | ||||||
| 11/06/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.91 | General |
| Category: Hematology | ||||||
| 09/28/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.86 | General |
| Category: Hematology | ||||||
| 09/19/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: ONCOLOGY | ||||||
| 09/07/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Oncology | ||||||
| 08/29/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/22/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Oncology | ||||||
| 07/28/2023 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 303 | 624 | $122,836 | $42,907 |
| 2022 | 7 | 431 | 859 | $156,308 | $56,502 |
| 2021 | 6 | 543 | 1,060 | $220,367 | $84,658 |
| 2020 | 6 | 481 | 1,054 | $192,961 | $58,444 |
Total Patients
1,758
Total Services
3,597
Medicare Billing
$242,511
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 106 | 388 | $79,929 | $28,404 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 120 | 159 | $21,816 | $7,207 | 33.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 50 | 50 | $13,965 | $4,782 | 34.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $3,885 | $1,560 | 40.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 16 | 16 | $3,241 | $953.62 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 158 | 506 | $99,176 | $36,595 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 163 | 234 | $31,122 | $10,278 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 33 | $8,745 | $3,586 | 41.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 25 | 25 | $6,853 | $2,488 | 36.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 31 | 31 | $4,818 | $1,673 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $4,234 | $1,450 | 34.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 17 | 17 | $1,360 | $431.29 | 31.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 83 | 416 | $110,240 | $44,867 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 163 | 262 | $51,352 | $17,852 | 34.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 211 | 296 | $39,345 | $13,850 | 35.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 35 | 35 | $10,850 | $4,607 | 42.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 22 | 22 | $5,390 | $1,788 | 33.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 29 | 29 | $3,190 | $1,693 | 53.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 255 | 756 | $148,176 | $43,706 | 29.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 111 | 165 | $21,922 | $6,205 | 28.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 33 | 43 | $11,395 | $3,717 | 32.6% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 55 | 55 | $6,138 | $3,020 | 49.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $3,410 | $1,357 | 39.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 16 | 24 | $1,920 | $439.13 | 22.9% |
About Dr. Donald Fleming, M.D
Dr. Donald Fleming, M.D is a Hematology & Oncology healthcare provider based in Elkins, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912976507.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Fleming, M.D has received a total of $10,103 in payments from pharmaceutical and medical device companies, with $3,516 received in 2024. These payments were reported across 126 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($6,652).
As a Medicare-enrolled provider, Fleming has provided services to 1,758 Medicare beneficiaries, totaling 3,597 services with total Medicare billing of $242,511. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Elkins, WV
- Active Since 03/16/2006
- Last Updated 12/08/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912976507
Products in Payments
- ELITEK (Biological) $750.00
- Venclexta (Drug) $615.00
- KEYTRUDA (Biological) $578.06
- CALQUENCE (Drug) $550.07
- IMFINZI (Biological) $525.00
- LYNPARZA (Drug) $525.00
- TAGRISSO (Drug) $525.00
- BRUKINSA (Drug) $300.00
- OPDIVO (Biological) $187.64
- FARYDAK (Drug) $150.00
- ZYTIGA (Drug) $149.31
- UNITUXIN (Drug) $100.00
- AFINITOR (Drug) $76.48
- ZEJULA (Drug) $74.96
- RETEVMO (Drug) $74.59
- ELITEK (Drug) $70.00
- PLUVICTO (Drug) $61.47
- TASIGNA (Drug) $52.41
- DOPTELET (Drug) $46.89
- REBLOZYL (Biological) $42.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.